<DOC>
	<DOCNO>NCT00426686</DOCNO>
	<brief_summary>Thrombotic thrombocytopenic purpura ( TTP ) thrombotic microangiopathy define spontaneous formation platelet thrombus microvessels . These platelet microthrombi responsible mechanical hemolytic anemia , thrombocytopenia multivisceral ischemia . TTP rare life-threatening disease absence appropriate treatment ( PLASMATHERAPY ) . The onset disease usually occur adulthood ( MOSCHCOVITZ syndrome ) rarely childhood ( UPSHAW-SCHULMAN syndrome ) . TTP either sporadic recurrent multiple unpredictable relapse . TTP pathophysiology remain obscure new metalloprotease , ADAMTS13 , demonstrate involved 90 % case . Physiologically , ADAMTS13 function consist limit size von Willebrand factor ( VWF ) multimers consequently , hemostatic capacity . A large majority TTP associate severe deficiency ADAMTS13 . In case , ADAMTS13 severe deficiency acquire via auto-antibodies ADAMTS13 ; rarely , ADAMTS13 deficiency hereditary via ADAMTS13 gene mutation . ADAMTS13 auto-antibodies either inhibitory catalytic activity non inhibitory . ADAMTS13 mutation spread gene . TTP prognosis quite heterogeneous . Indeed , one third patient , TTP refractory PLASMATHERAPY and/or chronic relapsing . Until , TTP prognosis factor know . Their identification however crucial adapt curative treatment acute episode ( addition first intention immunosuppressive agent PLASMATHERAPY ) prevent relapse . In context , aim current project identify ADAMTS13 related prognosis factor TTP . A national prospective multicenter study include adult pediatric patient TTP relate severe ADAMTS13 deficiency design three-year period . This study involve group French reference center ADAMTS13 10 clinical department various French hospital . Patients test ADAMTS13 activity antigen , ADAMTS13 antibodies ADAMTS13 gene sequence . Our main hypothesis inactivation ADAMTS13 domains crucial catalytic activity , either inhibitory auto-antibodies ( acquire TTP ) genetic mutation ( hereditary TTP ) major bad prognosis factor .</brief_summary>
	<brief_title>ADAMTS13 Thrombotic Thrombocytopenic Purpura</brief_title>
	<detailed_description>Thrombotic thrombocytopenic purpura ( TTP ) thrombotic microangiopathy define spontaneous formation platelet thrombus microvessels . These platelet microthrombi responsible mechanical hemolytic anemia , thrombocytopenia multivisceral ischemia . TTP rare life-threatening disease absence appropriate treatment ( PLASMATHERAPY ) . The onset disease usually occur adulthood ( MOSCHCOVITZ syndrome ) rarely childhood ( UPSHAW-SCHULMAN syndrome ) . TTP either sporadic recurrent multiple unpredictable relapse . TTP pathophysiology remain obscure new metalloprotease , ADAMTS13 , demonstrate involved 90 % case . Physiologically , ADAMTS13 function consist limit size von WILLBRAND factor ( VWF ) multimers consequently , hemostatic capacity . A large majority TTP associate severe deficiency ADAMTS13 activity lead accumulation ultra large VWF multimers plasma induce formation platelet microthrombi microcirculation . In case , ADAMTS13 severe deficiency acquire via auto-antibodies ADAMTS13 ; rarely , ADAMTS13 deficiency hereditary via ADAMTS13 gene mutation . ADAMTS13 auto-antibodies either inhibitory catalytic activity non inhibitory . ADAMTS13 mutation spread gene . TTP prognosis quite heterogeneous . Indeed , one third patient , TTP refractory PLASMATHERAPY and/or chronic relapsing . Until , TTP prognosis factor know . Their identification however crucial adapt curative treatment acute episode ( addition first intention immunosuppressive agent PLASMATHERAPY ) prevent relapse . In context , aim current project identify ADAMTS13 related prognosis factor TTP . A national prospective multicenter study include adult pediatric patient TTP relate severe ADAMTS13 deficiency design three-year period . This study involve group French reference center ADAMTS13 50 clinical department various French hospital . Patients test ADAMTS13 activity antigen , ADAMTS13 antibodies ADAMTS13 gene sequence . Our main hypothesis inactivation ADAMTS13 domains crucial catalytic activity , either inhibitory auto-antibodies ( acquire TTP ) genetic mutation ( hereditary TTP ) major bad prognosis factor .</detailed_description>
	<mesh_term>Purpura , Thrombocytopenic</mesh_term>
	<mesh_term>Purpura</mesh_term>
	<mesh_term>Purpura , Thrombotic Thrombocytopenic</mesh_term>
	<criteria>clinical suspicion TTP Hemoglobin level &lt; 10 g/dl ( adult ) &lt; 12 g/dl ( child ) Platelet level &lt; 150 giga/l ADAMTS13 activity &lt; 5 % Cancer Organ graft HIV infection</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>thrombotic thrombocytopenic purpura</keyword>
	<keyword>prognostic factor</keyword>
	<keyword>ADAMTS13</keyword>
</DOC>